Descovy (emtricitabine/tenofovir alafenamide) coverage
This document governs prior authorization and coverage rules for Descovy for members under Neighborhood Health Plan of Rhode Island Medicaid; it outlines approval criteria, quantity limits, and coverage duration for the drug.
No material clinical or coverage changes in this revision.
Coverage Criteria
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.